Analysis of effectiveness criteria in pharmacoeconomic studies of hypoglycemic drugs proposed for inclusion into the essential drug list in 2014-2016 in Russia

Abstract

Rationale. There is a certain variability of endpoints in diabetes pharmacoeconomic research in Russia. It makes difficult to compare the economical effectiveness of hypoglycemic drugs. Aim. To estimate a proportion of final and surrogate endpoints used as effectiveness criteria in pharmacoeconomic studies of hypoglycemic drugs proposed for inclusion into the Russian essential drug list in 2014-2016. Methods. 22 pharmacoeconomic studies on 12 hypoglycemic drugs were reviewed. Results. 8 effectiveness criteria were analyzed. Four of them (50%) were final endpoints. 26 of 41 outcomes (63%) related to final endpoints. The most often used endpoint was quality adjusted life years (QALY) - 62% of all final outcomes. The number of avoided cardiovascular events was another commonly used final endpoint (31 % of all hard outcomes). Change in glycated hemoglobin level was the most often used surrogate endpoint (73% of all surrogate outcomes). Conclusions. 1. At least one final endpoint was used in 19 of 20 studies (95%). 2. The most commonly used final endpoints are QALYs and the number of avoided cardiovascular events (93% of all hard outcomes). 3. Glycated hemoglobin level should not be used as the main effectiveness criteria determining the inclusion of drugs into the essential drug list.

Keywords

• фармакоэкономика
• жнвлп
• твёрдые точки
• суррогатные исходы
• сахарный диабет
• pharmacoeconomics
• essential drug list
• final endpoints
• surrogate endpoints
• type 2 diabetes mellitus